leadf
logo-loader
viewRedHill Biopharma

RedHill Biopharma COVID-19 treatment candidate better than Gilead’s remdesivir in lab test

Opaganib demonstrated "potent inhibition" of the virus in an in vitro model of human lung bronchial tissue

RedHill Biopharma - RedHill Biopharma COVID-19 treatment candidate better than Gilead’s remdesivir in lab test

RedHill Biopharma (NASDAQ:RDHL) announced its COVID-19 treatment candidate showed promising results in laboratory test.

Opaganib demonstrated "potent inhibition" of SARS-CoV-2, the virus that causes COVID-19, in an in vitro model of human lung bronchial tissue.

READ: Anger as US snaps up supplies of Gilead coronavirus treatment Remdesivir

It also compared favourably with remdesivir, the treatment developed by Gilead Sciences, Inc. (NASDAQ:GILD) and used in the US.

The candidate is under evaluation in global Phase 2/3 and US Phase 2 studies on humans for the treatment of severe COVID-19 pneumonia.

“We are accelerating progress toward our goal of generating a robust data package to potentially support emergency use authorisations for COVID-19,” said Mark L. Levitt, medical director at RedHill.

Shares advanced 10% to US$8.16 on Tuesday.

Quick facts: RedHill Biopharma

Price: 8.85 USD

NASDAQ:RDHL
Market: NASDAQ
Market Cap: $333.6 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of RedHill Biopharma named herein, including the promotion by the Company of RedHill Biopharma in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Redhill BioPharma presents at the Proactive One2One virtual conference

RedHill Biopharma Ltd's (Nasdaq: RDHL) Guy Goldberg pitches to investors at the Proactive One2One virtual conference. The company is a specialty biopharmaceutical company focussed on gastrointestinal and infectious diseases. They promote several GI drugs in the U.S with a robust late-stage...

on 10/30/2020

2 min read